Canadian Cancer Trials Group Bulletins

Trial Management Group

Canadian Cancer Trials Group MA.32

Canadian Cancer Trials Group MA.32, A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer, has been accruing extremely well at about 50 patients per month within Canada. To date there are 37 sites active and 339 patients enrolled -- almost 10% of the total accrual target! Thank you all for your enthusiasm and support of this trial -- you are making it happen!

We are very pleased to announce that beginning next week, CTSU sites will be able to enroll their first patients. We are thankful to our U.S. colleagues for their support and welcome their participation. With approximately 200 CTSU sites eager and ready to go, we expect our accrual to increase dramatically in the coming months.

If you have any questions or would like further information about this trial, please contact Catherine Elliott, Study Coordinator for MA.32, at 613-533-6430 or